Using Patient Blood Management With Erythropoietin to Treat Anemia in Adults Undergoing Coronary Artery Bypass Graft Surgery

What this Trial Is About

Anemia increases risks during coronary artery bypass grafting CABG, leading to more complications and higher mortality. Blood transfusions during cardiac surgery can cause negative outcomes, so erythropoietin EPO is studied as part of Patient Blood Management PBM to reduce transfusion needs and improve recovery. This Phase 2 study compares three groups non-anemic controls, anemic patients treated with blood transfusions, and anemic patients treated with EPO, to assess various clinical and inflammatory outcomes. Participants are assigned to one of three groups a Control Group of non-anemic patients, a Non-PBM Group receiving blood transfusions as needed, and a PBM Group treated with EPO before surgery. EPO is given via subcutaneous or intravenous routes with specific dosing schedules depending on time before surgery and iron supplementation if needed. The Non-PBM group receives red blood cell transfusions after surgery based on hemoglobin levels. The study focuses on reducing or eliminating transfusions in the perioperative period. During the study, researchers will measure the average number of red blood cell units given until three days after surgery, length of ICU and hospital stays, mechanical ventilation time, need for dialysis, bleeding, infections, inflammatory and epigenetic changes, cardiac events like stroke and myocardial infarction, hemoglobin levels, and mortality. The study also considers demographic and clinical factors. Participants are followed from surgery until hospital discharge to evaluate these outcomes.

PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG)